BGB-11417-105

{ "short_title": "BGB-11417-105", "data_mode": "910", "data_mode_number": "000000029", "official_title": null, "accrual_state": "running", "therapeutic_value": "not_applicable", "therapieansatz_value": "not_applicable", "therapieintervention_value": "not_applicable", "therapielinie_value": "rezidiv_haema", "ctgov_number": null, "eudract_number": null, "general_contact_email": "sal-aml-register@ukdd.de", "general_contact_phone": "+49 351-45818380", "hauptpruefer_dd_name": null, "description_laie_de": "Eine Phase-1b/2-Studie mit BGB-11417 in Monotherapie und in verschiedenen Kombinationen mit Dexamethason plus Carfilzomib, Dexamethason plus Daratumumab und Dexamethason plus Pomalidomid beim Multiplen Myelom", "description_laie_en": "A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, \r\nDexamethasone plus Daratumumab, and Dexamethasone plus Pomalidomide in Multiple Myeloma", "description_expert_de": "Eine Phase-1b/2-Studie mit BGB-11417 in Monotherapie und in verschiedenen Kombinationen mit Dexamethason plus Carfilzomib, Dexamethason plus Daratumumab und Dexamethason plus Pomalidomid beim Multiplen Myelom", "description_expert_en": "A Phase 1b/2 Study of BGB-11417 in Monotherapy and in Various Combinations with Dexamethasone plus Carfilzomib, \r\nDexamethasone plus Daratumumab, and Dexamethasone plus Pomalidomide in Multiple Myeloma", "rechtsgrundlage_value": null, "phase_amg_value": null, "main_cat_id": 4, "sub_cat_id": 26 }